RMRachael Morkem

Rachael Morkem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rachael Morkem has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • David Barber

    Department of Family Medicine, Queen’s University, Kingston, Canada

    2 shared publications
  • Alexander G. Singer

    Associate Professor and Director of Research and Quality Improvement in the Department of Family Medicine at the University of Manitoba in Winnipeg and Director of the Manitoba Primary Care Research Network

    1 shared publication
  • Braden Knight

    Public Health Agency of Canada, Ottawa, Canada

    1 shared publication
  • Glenys Smith

    Public Health Agency of Canada, Ottawa, Canada

    1 shared publication
  • Olivia Spohn

    Family physician in Kingston, Ont

    1 shared publication
  • Sabrina T. Wong

    Centre for Health Services and Policy Research and School of Nursing, University of British Columbia, Vancouver, Canada

    1 shared publication

Latest Publications

  • Open Access

    Understanding the impact of COVID-19 on antibiotic use in Canadian primary care: a matched-cohort study using EMR data

    by Rachael Morkem, Glenys Smith, Braden Knight, Sabrina T. Wong, David Barber

    Background: Inappropriate or overuse of antibiotic prescribing in primary care highlights an opportunity for antimicrobial stewardship (AMS) programs aimed at reducing unnecessary use of antimicrobials through education, policies and practice audits that optimize antibiotic prescribing. Evidence from the early part of the pandemic indicates a high rate of prescribing of antibiotics for patients with COVID-19. It is crucial to surveil antibiotic prescribing by primary care providers from the start of the pandemic and into its endemic stage to understand the effects of the pandemic and better target effective AMS programs. Methods: This was a matched pair population-based cohort study that used electronic medical record (EMR) data from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN). Participants included all patients that visited their primary care provider and met the inclusion criteria for COVID-19, respiratory tract infection (RTI), or non-respiratory or influenza-like-illness (negative). Four outcomes were evaluated (a) receipt of an antibiotic prescription; (b) receipt of a non-antibiotic prescription; (c) a subsequent primary care visit (for any reason); and (d) a subsequent primary care visit with a bacterial infection diagnosis. Conditional logistic regression was used to evaluate the association between COVID-19 and each of the four outcomes. Each model was adjusted for location (rural or urban), material and social deprivation, smoking status, alcohol use, obesity, pregnancy, HIV, cancer and number of chronic conditions. Results: The odds of a COVID-19 patient receiving an antibiotic within 30 days of their visit is much lower than for patients visiting for RTI or for a non-respiratory or influenza-like-illnesses (AOR = 0.08, 95% CI[0.07, 0.09] compared to RTI, and AOR = 0.43, 95% CI[0.38, 0.48] compared to negatives). It was found that a patient visit for COVID-19 was much less likely to have a subsequent visit for a bacterial infection at all time points. Conclusions: Encouragingly, COVID-19 patients were much less likely to receive an antibiotic prescription than patients with an RTI. However, this highlights an opportunity to leverage the education and attitude change brought about by the public health messaging during the COVID-19 pandemic (that antibiotics cannot treat a viral infection), to reduce the prescribing of antibiotics for other viral RTIs and improve antibiotic stewardship.

  • Open Access

    Prevalence and management of dyslipidemia in primary care practices in Canada

    by Olivia Spohn, Rachael Morkem, Alexander G. Singer, David Barber

    Objective To estimate the prevalence of dyslipidemia and to describe its management in Canadian primary care. Design Retrospective cohort study using primary care electronic medical record data. Setting Canada. Participants Adults aged 40 years or older who saw a Canadian Primary Care Sentinel Surveillance Network contributor between January 1, 2018, and December 31, 2019. Main outcome measures Presence or absence of dyslipidemia as identified by a validated case definition and the treatment status of patients identified as having dyslipidemia based on having been prescribed a lipid-lowering agent (LLA). Results In total, 50.0% of the 773,081 patients 40 years of age or older who had had a primary care visit in 2018 or 2019 were identified as having dyslipidemia. Dyslipidemia was more prevalent in patients 65 or older (61.5%), in males (56.7%) versus females (44.7%), and in those living in urban areas (50.0%) versus rural areas (45.2%). In patients with documented dyslipidemia, 42.8% had evidence of treatment with an LLA. Stratifying patients by Framingham risk score revealed that those in the high-risk category were more likely to have been prescribed an LLA (65.0%) compared with those in the intermediate-risk group (48.7%) or the low-risk group (22.8%). The strongest determinants of receiving LLA treatment for dyslipidemia include sex, with males being 1.95 times more likely to have been treated compared with females (95% CI 1.91 to 1.98; P<.0001); and body mass index, with those with obesity having a significantly increased likelihood of being treated with an LLA (adjusted odds ratio of 1.36, 95% CI 1.32 to 1.41; P<.0001). Conclusion This study provides an updated look at the prevalence and treatment of dyslipidemia among Canadians. Half of patients aged 40 years or older have dyslipidemia, with an even higher prevalence observed among adults aged 65 years or older, males, and those with obesity or other chronic conditions. There are still gaps in treatment among those with documented dyslipidemia, principally among those calculated to have high or intermediate Framingham risk scores. Particular attention should also be paid to those at higher risk for not receiving treatment, including female patients and those within normal body mass index ranges. Résumé Objectif Estimer la prévalence de la dyslipidémie et décrire sa prise en charge par les soins primaires au Canada. Type d’étude Une étude rétrospective de cohortes à l’aide des données de dossiers médicaux électroniques en soins primaires. Contexte Canada. Participants Les adultes âgés de 40 ans ou plus ayant consulté un médecin contributeur du Réseau canadien de surveillance sentinelle, entre le 1er janvier 2018 et le 31 décembre 2019. Principaux paramètres à l’étude La présence ou l’absence de dyslipidémie telle que déterminée par une définition de cas validée, et l’état du traitement des patients identifiés comme ayant une dyslipidémie, fondé sur le fait d’avoir reçu une prescription d’un agent hypolipidémiant (AHL). Résultats Au total, 50,0 % des 773 081 patients de 40 ans ou plus qui avaient consulté en soins primaires en 2018 ou 2019 ont été identifiés comme ayant une dyslipidémie. La dyslipidémie était plus fréquente chez les patients de 65 ans ou plus (61,5 %), chez les hommes (56,7 %) que chez les femmes (44,7 %), chez les personnes vivant en milieu urbain (50,0 %) plutôt qu’en milieu rural (45,2 %). Une preuve de traitement avec un AHL a été constatée chez 32,5 % des patients ayant une dyslipidémie. La stratification des patients selon le score de risque de Framingham a révélé que ceux dans la catégorie à risque élevé étaient plus susceptibles d’avoir reçu une prescription d’AHL (65,0 %) que ceux dans le groupe à risque intermédiaire (48,7 %) ou dans le groupe à faible risque (22,8 %). Parmi les principaux déterminants d’un traitement par AHL pour la dyslipidémie figuraient le sexe, notamment une probabilité d’être traités 1,95 fois plus élevée chez les hommes que chez les femmes (IC à 95 % de 1,91 à 1,98; p<,0001); et l’indice de masse corporelle, les personnes obèses ayant une probabilité significativement plus élevée d’être traitées avec un AHL (rapport de cotes rajusté de 1,36, IC à 95 % de 1,32 à 1,41; p<,0001). Conclusion Cette étude présente un aperçu actualisé de la prévalence et du traitement de la dyslipidémie chez les Canadiens. La moitié des patients de 40 ans et plus ont une dyslipidémie, et la prévalence la plus élevée est observée chez les adultes de 65 ans ou plus, les hommes, et les personnes obèses ou ayant d’autres problèmes chroniques. Il existe encore des lacunes dans le traitement des personnes dont la dyslipidémie est documentée, principalement chez celles dont les scores de risque de Framingham calculés sont élevés ou intermédiaires. Une attention particulière devrait aussi être accordée aux personnes dont le risque est plus élevé si elles ne sont pas traitées, y compris les femmes et les patients dont l’indice de masse corporelle se situe dans les valeurs normales.